Elena Garralda

Also affiliated with Instituto Oncológico Dr. Rosell, Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari

MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 11 papers. Top paper: “Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study”.

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

The Lancet Diabetes & Endocrinology(2021)10.1016/s2213-8587(21)00120-0

N/A

5.1DataRank · unranked

354 citations

Mimi I. Hu, Lori J. Wirth, Martin Schüler, Aaron S. Mansfield, Giuseppe Curigliano +20 more

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

The Lancet Oncology(2021)10.1016/s1470-2045(21)00247-3

N/A

5.0DataRank · unranked

445 citations

Giuseppe Curigliano, Dong‐Wan Kim, Ki Hyeong Lee, Benjamin Besse, Christina S. Baik +20 more

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Nature Medicine(2022)10.1038/s41591-022-01931-y

N/A

3.9DataRank · unranked

240 citations

Philippe A. Cassier, Salvatore Siena, Elena Garralda, Luis Paz‐Ares, Pilar Garrido +14 more

A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAFV600E-MutantKRASWild-Type Metastatic Colorectal Cancer

The Oncologist(2023)10.1093/oncolo/oyad007

N/A

1.2DataRank · unranked

53 citations

Eric Van Cutsem, Elena Garralda, David Tai, Filippo de Braud, Ravit Geva +9 more

Delivering precision oncology to patients with cancer

Nature Medicine(2022)10.1038/s41591-022-01717-2

N/A

0.885DataRank · unranked

365 citations

Lotte Steuten, Philippe Aftimos, Fabrice Andre, Mark Davies, Elena Garralda +10 more

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

Annals of Oncology(2022)10.1016/j.annonc.2022.08.002

N/A

0.782DataRank · unranked

183 citations

Giuseppe Curigliano, Michael Thomas, Vivek Subbiah, Christina S. Baik, Daniel S.W. Tan +21 more

Manufacturing‐dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development

Clinical and Translational Science(2022)10.1111/cts.13387

N/A

0.655DataRank · unranked

16 citations

Aaron R. Hansen, Glenn J. Hanna, Elena Garralda, Haeseong Park, James Strauss +11 more

Uzatresgene autoleucel autologous T-cell monotherapy for advanced solid tumors: SURPASS, a phase 1, open-label trial

10.21203/rs.3.rs-9238113/v1

N/A

0DataRank · unranked

0 citations

Victor Moreno, Kathleen Moore, Adam Asch, Brian A. Van Tine, John Charlson +31 more

592 Phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: part 1 results

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.0592

N/A

0DataRank · unranked

2 citations

Richard D. Carvajal, Diwakar Davar, Eduardo Castañón, Paolo A. Ascierto, Emiliano Calvo +16 more

176P Enhancing immunotherapy response prediction via multimodal integration of radiology and pathology deep learning models

Annals of Oncology(2023)10.1016/j.annonc.2023.09.2900

N/A

0DataRank · unranked

1 citations

Omar S. M. El Nahhas, Óscar Palomares, V. Navarro, Irene Sansano, G. Serna +9 more

First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-1991

N/A

0DataRank · unranked

21 citations

Omar Saavedra, Jacob Thomas, Claire Livings, Elena Garralda, Gabriele Hintzen +16 more